CVS HEALTH Corp: Form 10-Q for the period ended Sep 30, 2017
Filed with the SEC on Nov 6, 2017 and accepted by EDGAR at Nov 6, 2017, 16:50 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2017-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2017-07-01 to 2017-09-30 | $46.18bn | us-gaap:Revenues |
| Revenue | 9 months2017-01-01 to 2017-09-30 | $136.38bn | us-gaap:Revenues |
| Cost of revenue | 3 months2017-07-01 to 2017-09-30 | $39.05bn | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2017-01-01 to 2017-09-30 | $115.74bn | us-gaap:CostOfRevenue |
| Gross profit | 3 months2017-07-01 to 2017-09-30 | $7.13bn | us-gaap:GrossProfit |
| Gross profit | 9 months2017-01-01 to 2017-09-30 | $20.64bn | us-gaap:GrossProfit |
| Operating income | 3 months2017-07-01 to 2017-09-30 | $2.50bn | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2017-01-01 to 2017-09-30 | $6.41bn | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2017-07-01 to 2017-09-30 | $777.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2017-01-01 to 2017-09-30 | $2.12bn | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2017-07-01 to 2017-09-30 | $1.28bn | us-gaap:NetIncomeLoss |
| Net income | 9 months2017-01-01 to 2017-09-30 | $3.33bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2017-07-01 to 2017-09-30 | $1.26 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2017-01-01 to 2017-09-30 | $3.24 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2017-07-01 to 2017-09-30 | $1.26 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2017-01-01 to 2017-09-30 | $3.25 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2017-07-01 to 2017-09-30 | 1,020,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2017-01-01 to 2017-09-30 | 1,026,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2017-01-01 to 2017-09-30 | $8.14bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2017-01-01 to 2017-09-30 | $1.41bn | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months2017-01-01 to 2017-09-30 | $1.54bn | us-gaap:PaymentsOfDividends |
| Share repurchases | 9 months2017-01-01 to 2017-09-30 | $4.36bn | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2017-09-30 | $2.48bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2017-09-30 | $29.92bn | us-gaap:AssetsCurrent |
| Total assets | At period end2017-09-30 | $92.85bn | us-gaap:Assets |
| Current liabilities | At period end2017-09-30 | $28.51bn | us-gaap:LiabilitiesCurrent |
| Long-term debt | At period end2017-09-30 | $23.39bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2017-09-30 | $2.29bn | us-gaap:LongTermDebtCurrent |
| Short-term borrowings | At period end2017-09-30 | $110.0m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | At period end2017-09-30 | $34.86bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001558370-17-008250. Last ingested by Listed: Nov 6, 2026, 17:47 ET. Listed shows no prices and gives no investment advice.